natgillin/translations-raw huggingface dataset:
Dose adjustment may also be required, for example, if the patient's weight or life-style changes, change of timing of insulin dose or other circumstances arise that increase susceptibility to hypo-or hyperglycaemia (see section 4.4).
Prilagoditev odmerka je lahko potrebna tudi, če se npr. spremeni bolnikova telesna masa, način življenja ali čas apliciranja insulina, ali se pojavijo kakšne druge okoliščine, ki povečajo nagnjenost k hipo - ali hiperglikemiji (glejte poglavje 4. 4).
Mixing or diluting can change its time/ action profile and mixing can cause precipitation.
Mešanje ali redčenje lahko spremeni profil časovnega poteka in delovanje; mešanje lahko povzroči precipitacijo.
Due to limited experience the efficacy and safety of Lantus could not be assessed in the following groups of patients: patients with impaired liver function or patients with moderate/ severe renal impairment (see section 4.4).
Zaradi omejenih izkušenj učinkovitosti in varnosti zdravila Lantus ni bilo mogoče oceniti pri bolnikih z okvarjenim delovanjem jeter in bolnikih z zmerno ali hudo okvaro ledvic (glejte poglavje 4. 4).
Safety and efficacy of Lantus have been established in adolescents and children of 6 years and above.
Varnost in učinkovitost zdravila Lantus sta potrjeni pri mladostnikih in otrocih, starih 6 let ali več.
Due to limited experience the efficacy and safety of Lantus could not be assessed in children below 6 years of age, in patients with impaired liver function or in patients with moderate/ severe renal impairment (see section 4.2).
Zaradi omejenih izkušenj učinkovitosti in varnosti zdravila Lantus ni bilo mogoče oceniti pri otrocih do 6. leta starosti, bolnikih z okvarjenim delovanjem jeter in bolnikih z zmerno ali hudo okvaro ledvic (glejte poglavje 4. 2).
In patients with renal impairment, insulin requirements may be diminished due to reduced insulin metabolism.
Pri bolnikih z okvaro ledvic se lahko potreba po insulinu zmanjša zaradi zmanjšane presnove insulina.
3 In case of insufficient glucose control or a tendency to hyper- or hypoglycaemic episodes, the patient's adherence to the prescribed treatment regimen, injection sites and proper injection technique and all other relevant factors must be reviewed before dose adjustment is considered.
3 V primeru nezadostne urejenosti glukoze ali nagnjenosti k hiper - ali hipoglikemijam je treba pred spreminjanjem odmerka preveriti, ali bolnik upošteva predpisano shemo zdravljenja, mesta injiciranja, ustrezno tehniko injiciranja in vse druge pomembne dejavnike.
(See section 4.8)
V redkih primerih je zaradi obstoja takšnih protiteles proti insulinu treba prilagoditi odmerek insulina, da bi odpravili nagnjenost k hiper - ali hipoglikemiji (glejte poglavje 4. 8).
- in whom glycaemic control is markedly improved,
- ki se jim urejenost glikemije občutno izboljša,
Adherence of the patient to the dosage and dietary regimen, correct insulin administration and awareness of hypoglycaemia symptoms are essential to reduce the risk of hypoglycaemia.
Za zmanjšanje tveganja za hipoglikemijo mora bolnik nujno upoštevati shemo odmerjanja in načrt prehrane, pravilno aplicirati insulin in poznati simptome hipoglikemije.
4
4 Sočasne bolezni
Intercurrent illness
V primeru sočasnih bolezni je potreben intenzivnejši nadzor presnove.
Substances that may enhance the blood-glucose-lowering effect and increase susceptibility to hypoglycaemia include oral antidiabetic agents, angiotensin converting enzyme (ACE) inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, pentoxifylline, propoxyphene, salicylates and sulfonamide antibiotics.
Med zdravili, ki lahko stopnjujejo učinek znižanja glukoze v krvi in povečajo nagnjenost k hipoglikemiji, so peroralni antidiabetiki, zaviralci angiotenzinske konvertaze (ACE), dizopiramid, fibrati, fluoksetin, zaviralci monoaminooksidaze (MAO), pentoksifilin, propoksifen, salicilati in sulfonamidni antibiotiki.
Substances that may reduce the blood-glucose-lowering effect include corticosteroids, danazol, diazoxide, diuretics, glucagon, isoniazid, oestrogens and progestogens, phenothiazine derivatives, somatropin, sympathomimetic agents (e. g. epinephrine [adrenaline], salbutamol, terbutaline), thyroid hormones, atypical antipsychotic medicinal products (e. g. clozapine and olanzapine) and protease inhibitors.
Med zdravili, ki lahko zmanjšajo učinek znižanja glukoze v krvi, so kortikosteroidi, danazol, diazoksid, diuretiki, glukagon, izoniazid, estrogeni in progestogeni, fenotiazinski derivati, somatropin, simpatikomimetiki (npr. adrenalin, salbutamol, terbutalin), ščitnični hormoni, atipični antipsihotiki (npr. klozapin in olanzapin) in zaviralci proteaz.
Beta-blockers, clonidine, lithium salts or alcohol may either potentiate or weaken the blood-glucose- lowering effect of insulin.
Zaviralci adrenergičnih receptorjev beta, klonidin, litijeve soli ali alkohol lahko učinek znižanja glukoze v krvi pri insulinu bodisi stopnjujejo ali oslabijo.
Pregnancy For insulin glargine no clinical data on exposed pregnancies from controlled clinical trials are available.
Nosečnost Za insulin glargin ni na voljo kliničnih podatkov iz nadzorovanih kliničnih preskušanj od nosečnic, ki so bile izpostavljene zdravilu.
A limited number of exposed pregnancies from Post Marketing Surveillance indicate no adverse effects of insulin glargine on pregnancy or on the health of the foetus and newborn child.
Podatki iz nadzora po uvedbi na trg pri omejenem številu nosečnic, ki so bile izpostavljene zdravilu, ne kažejo na možnost škodljivih vplivov insulina glargin na nosečnost ali zdravje zarodka in novorojenca.
Animal studies do not indicate direct harmful effects with respect to pregnancy, embryonal / foetal development, parturition or postnatal development (see section 5.3).
Študije na živalih ne kažejo na neposredne škodljive vplive na nosečnost, razvoj zarodka/ plodu, porod ali postnatalni razvoj (glejte poglavje 5. 3).
The use of Lantus may be considered in pregnancy, if necessary.
Pri predpisovanju zdravila nosečnicam je potrebna previdnost.
Lactation Lactating women may require adjustments in insulin dose and diet.
Dojenje Pri doječih ženskah utegne biti potrebna prilagoditev odmerka insulina in prehrane.
5 The patient's ability to concentrate and react may be impaired as a result of hypoglycaemia or hyperglycaemia or, for example, as a result of visual impairment.
Bolnikova zmožnost koncentracije in reagiranja se lahko poslabša zaradi hipoglikemije ali hiperglikemije, pa tudi npr. zaradi prizadetosti vida.
Hypoglycaemia, in general the most frequent undesirable effect of insulin therapy, may occur if the insulin dose is too high in relation to the insulin requirement.
Hipoglikemija, na splošno najpogostejši neželeni učinek zdravljenja z insulinom, se lahko pojavi, če je odmerek insulina prevelik glede na potrebo po insulinu.
The following related adverse reactions from clinical investigations were listed below by system organ class and in order of decreasing incidence (very common: ≥ 1/ 10; common: ≥ 1/ 100 to < 1/ 10; uncommon: ≥ 1/ 1,000 to < 1/ 100; rare: ≥ 1/ 10,000 to < 1/ 1,000; very rare: < 1/ 10,000).
Naslednji povezani neželeni učinki, ugotovljeni v kliničnih raziskavah, so navedeni spodaj po organskih sistemih in razvrščeni po padajoči incidenci (zelo pogosti: ≥ 1/ 10; pogosti: ≥ 1/ 100 do < 1/ 10; občasni: ≥ 1/ 1. 000 do < 1/ 100; redki: ≥ 1/ 10. 000 do < 1/ 1. 000; zelo redki: < 1/ 10. 000).
Hypoglycaemia Severe hypoglycaemic attacks, especially if recurrent, may lead to neurological damage.
Zelo pogosti: hipoglikemija Hude hipoglikemije lahko povzročijo nevrološke okvare, zlasti če se ponavljajo.
Allergic reaction Immediate-type allergic reactions to insulin are rare.
Redki: alergijske reakcije Takojšnje alergijske reakcije na insulin so redke.
In rare cases, the presence of such insulin antibodies may necessitate adjustment of the insulin dose in order to correct a tendency to hyper- or hypoglycaemia.
V redkih primerih je zaradi prisotnosti insulinskih protiteles treba prilagoditi odmerek insulina, da bi odpravili nagnjenost k hiper - ali hipoglikemiji.
Dysgeusia
Zelo redki: motnje okusa
Visual impairment A marked change in glycaemic control may cause temporary visual impairment, due to temporary alteration in the turgidity and refractive index of the lens.
Redki: poslabšanje vida Izrazita sprememba glikemične urejenosti lahko prehodno poslabša vid zaradi prehodno spremenjenega turgorja in lomnega količnika leče.
Retinopathy Long-term improved glycaemic control decreases the risk of progression of diabetic retinopathy.
Redki: retinopatija Dolgoročno izboljšanje glikemične urejenosti zmanjša tveganje za napredovanje diabetične retinopatije.
However, intensification of insulin therapy with abrupt improvement in glycaemic control may be
Vendar se lahko z intenziviranjem insulinskega zdravljenja in nenadnim izboljšanjem glikemične urejenosti diabetična retinopatija prehodno poslabša.
6 associated with temporary worsening of diabetic retinopathy.
6 Bolezni kože in podkožja
Lipohypertrophy
Pogosti: lipohipertrofija
Lipoatrophy
Občasni: lipoatrofija
Myalgia
Zelo redki: mialgija
Injection site reactions Such reactions include redness, pain, itching, hives, swelling, or inflammation.
Pogosti: reakcije na injekcijskem mestu
Oedema Rarely, insulin may cause sodium retention and oedema particularly if previously poor metabolic control is improved by intensified insulin therapy.
Redki: edemi Redko lahko insulin povzroči zadrževanje natrija in edeme, še zlasti, če intenzivirano insulinsko zdravljenje izboljša presnovno urejenost, ki je bila prej slaba.
In general, the safety profile for patients ≤ 18 years of age is similar to the safety profile for patients > 18 years.
Navadno je varnostni profil bolnikov, starih ≤ 18 let, podoben varnostnemu profilu bolnikov starih > 18 let.
The adverse event reports received from Post Marketing Surveillance included relatively more frequent injection site reactions (injection site pain, injection site reaction) and skin reactions (rash, urticaria) in patients ≤ 18 years of age than in patients > 18 years.
Med neželenimi učinki, poročanimi v postmarketinških raziskavah, se pri bolnikih starih ≤ 18 let v primerjavi z bolniki starimi > 18 let, relativno pogosteje pojavljajo reakcije na injekcijskem mestu (bolečina na injekcijskem mestu, reakcija na injekcijskem mestu) in kožne reakcije (srbenje, urtikarija).
No clinical study safety data are available in patients below 6 years of age.
Klinične raziskave o varnosti pri bolnikih starih pod 6 let niso na voljo.
More severe episodes with coma, seizure, or neurologic impairment may be treated with intramuscular/ subcutaneous glucagon or concentrated intravenous glucose.
Hujše primere s komo, generaliziranimi krči ali nevrološko prizadetostjo je mogoče zdraviti z glukagonom intramuskularno ali subkutano oz. s koncentrirano glukozo intravensko.
5.1 Pharmacodynamic properties 7 Pharmacotherapeutic group:
Farmakoterapevtska skupina:
Insulins and analogues for injection, long-acting.
Insulini za injiciranje z dolgotrajnim delovanjem in analogi.
After injection into the subcutaneous tissue, the acidic solution is neutralised leading to formation of micro-precipitates from which small amounts of insulin glargine are continuously released, providing a smooth, peakless, predictable concentration/ time profile with a prolonged duration of action.
To zagotavlja enakomeren, predvidljiv časovni potek koncentracije brez vrhov ter podaljšano delovanje.
Insulin receptor binding:
Vezava na insulinske receptorje:
Insulin glargine is very similar to human insulin with respect to insulin receptor binding kinetics.
Insulin glargin je po kinetiki vezave na insulinske receptorje zelo podoben humanemu insulinu.
It can, therefore, be considered to mediate the same type of effect via the insulin receptor as insulin.
Zato velja, da prek insulinskih receptorjev posreduje isto vrsto učinka kot insulin.
Activity Profile in Patients with Type 1 Diabetes
Potek delovanja pri bolnikih z diabetesom tipa 1
*determined as amount of glucose infused to maintain constant plasma glucose levels (hourly mean values)
* določena kot količina infundirane glukoze, potrebna za vzdrževanje stalne koncentracije glukoze v plazmi (povprečne urne vrednosti)
The longer duration of action of insulin glargine is directly related to its slower rate of absorption and supports once daily administration.
Dolgotrajnejše delovanje insulina glargin je neposredno povezano z njegovo počasnejšo absorpcijo in podpira uporabo enkrat na dan.
8 In a clinical study, symptoms of hypoglycaemia or counter-regulatory hormone responses were similar after intravenous insulin glargine and human insulin both in healthy volunteers and patients with type 1 diabetes.
8 V klinični študiji so bili simptomi hipoglikemije in protiregulacijski hormonski odzivi po intravenski uporabi insulina glargin in humanega insulina pri zdravih prostovoljcih in bolnikih z diabetesom tipa 1 podobni.
Effects of Lantus (once daily) on diabetic retinopathy were evaluated in an open-label 5-year NPH- controlled study (NPH given bid) in 1024 type 2 diabetic patients in which progression of retinopathy by 3 or more steps on the Early Treatment Diabetic Retinopathy Study (ETDRS) scale was investigated by fundus photography.
V študijah so napredek retinopatije za tri ali več stopenj po lestvici ETDRS (Early Treatment Diabetic Retinopathy Study) preiskovali s slikanjem očesnega ozadja.
No significant difference was seen in the progression of diabetic retinopathy when Lantus was compared to NPH insulin.
Ko so primerjali zdravilo Lantus z insulinom NPH, pri razvoju diabetične retinopatije niso opazili pomembnih razlik.
In man, insulin glargine is partly degraded in the subcutaneous tissue at the carboxyl terminus of the Beta chain with formation of the active metabolites 21A-Gly-insulin and 21A -Gly-des-30B-Thr-insulin.
Pri človeku se insulin glargin deloma razgradi v podkožnem tkivu na karboksilnem koncu verige beta; nastaneta aktivna presnovka 21A- Gly- insulin in 21A- Gly- des- 30B- Thr insulin.
Unchanged insulin glargine and degradation products are also present in the plasma.
Nespremenjeni insulin glargin in razgradni produkti so prisotni tudi v plazmi.
Zinc chloride, m-cresol, glycerol, hydrochloric acid, sodium hydroxide, water for injections.
5 ml viala: cinkov klorid, metakrezol, glicerol, klorovodikova kislina, natrijev hidroksid, voda za injekcije.
Zinc chloride, m-cresol, glycerol, hydrochloric acid, Polysorbate 20, sodium hydroxide, water for injections
10 ml viala: cinkov klorid, metakrezol, glicerol, klorovodikova kislina, polisorbat 20,
9 6.2 Incompatibilities
9 natrijev hidroksid, voda za injekcije.
Shelf-life after first use of the vial The product may be stored for a maximum of 4 weeks not above 25°C away from direct heat or direct light.
Rok uporabnosti po prvi uporabi viale Zdravilo lahko shranjujete največ 4 tedne pri temperaturi do 25 °C zaščiteno pred neposredno toploto ali svetlobo.
Unopened vials Store in a refrigerator (2°C-8°C).
Neodprte viale Shranjujte v hladilniku (2 °C - 8 °C).
Do not put Lantus next to the freezer compartment or a freezer pack.
Zdravila Lantus ne shranjujte v bližini zamrzovalnega razdelka ali zamrzovalnega vložka.
5 ml solution in a vial (type 1 colourless glass) with a flanged cap (aluminium), a stopper (chlorobutyl rubber (type 1)) and a tear-off cap (polypropylene).
5 ml raztopine v viali (iz brezbarvnega stekla tipa 1) s prirobljeno zaporko (iz aluminija), z zamaškom (iz klorobutilne gume (tipa 1)) in s pokrovčkom, ki se odtrga (iz polipropilena).
Packs of 1, 2, 5 and 10 vials are available.
Na voljo so pakiranja z 1, 2, 5 in 10 vialami.
10 ml solution in a vial (type 1 colourless glass) with a flanged cap (aluminium), (type 1, laminate of polyisoprene and bromobutyl rubber) a stopper and a tear-off cap (polypropylene).
10 ml raztopine v viali (iz brezbarvnega stekla tipa 1) s prirobljeno zaporko (iz aluminija), z zamaškom (tip 1, iz poliizoprenskega laminata in brombutilne gume) in s pokrovčkom, ki se odtrga (iz polipropilena).
Packs of 1 vial are available.
Na voljo so pakiranja z 1 vialo.
Sanofi-Aventis Deutschland GmbH, D-65926 Frankfurt am Main, Germany.
Sanofi- Aventis Deutschland GmbH, D- 65926 Frankfurt am Main, Nemčija.
10 Date of first authorisation:
Datum prve odobritve:
9 June 2000 Date of latest renewal:
9. junij 2000 Datum zadnjega podaljšanja:
9 June 2005
9. junij 2005
Lantus 100 Units/ ml solution for injection in a cartridge.
Lantus 100 enot/ ml raztopina za injiciranje v vložku
To reduce the risk of nocturnal and early morning hypoglycaemia, patients who are changing their basal insulin regimen from a twice daily NPH insulin to a once daily regimen with Lantus should reduce their daily dose of basal insulin by 20-30% during the first weeks of treatment.
Bolniki, ki z insulina NPH dvakrat na dan preidejo na zdravilo Lantus enkrat na dan, morajo za zmanjšanje nevarnosti nočne in zgodnje jutranje hipoglikemije dnevni odmerek bazalnega insulina v
12 During the first weeks the reduction should, at least partially, be compensated by an increase in mealtime insulin, after this period the regimen should be adjusted individually.
V prvih tednih je treba to zmanjšanje vsaj delno nadomestiti s povečanjem odmerkov insulina ob obrokih, po tem obdobju pa je zdravljenje treba prilagajati individualno.
13 In case of insufficient glucose control or a tendency to hyper- or hypoglycaemic episodes, the patient's adherence to the prescribed treatment regimen, injection sites and proper injection technique and all other relevant factors must be reviewed before dose adjustment is considered.
13 V primeru nezadostne urejenosti glukoze ali nagnjenosti k hiper - ali hipoglikemijam je treba pred spreminjanjem odmerka preveriti, ali bolnik upošteva predpisano shemo zdravljenja, mesta injiciranja, ustrezno tehniko injiciranja in vse druge pomembne dejavnike.
- certain uncompensated endocrine disorders, (e. g. in hypothyroidism and in anterior pituitary or
- določene nekompenzirane endokrine motnje (npr. hipotiroidizem, insuficienca sprednjega
14 Intercurrent illness
14 Sočasne bolezni
15 The patient's ability to concentrate and react may be impaired as a result of hypoglycaemia or hyperglycaemia or, for example, as a result of visual impairment.
Bolnikova zmožnost koncentracije in reagiranja se lahko poslabša zaradi hipoglikemije ali hiperglikemije, pa tudi npr. zaradi prizadetosti vida.
Patients should be advised to take precautions to avoid hypoglycaemia whilst driving.
15 Bolnikom je treba svetovati, naj upoštevajo ustrezne varnostne ukrepe, da bi se izognili hipoglikemiji med upravljanjem vozila.
In patients with proliferative retinopathy,
Pri bolnikih s proliferativno retinopatijo lahko hude hipoglikemije povzročijo prehodno slepoto, zlasti če retinopatija ni zdravljena s fotokoagulacijo.
16 particularly if not treated with photocoagulation, severe hypoglycaemic episodes may result in transient amaurosis.
16 Bolezni kože in podkožja
Injection site reactions Such reactions include redness, pain, itching, hives, swelling, or inflammation.
Pogosti: reakcije na injekcijskem mestu Med takšnimi reakcijami so pordelost, bolečine, srbenje, urtikarija, otekanje ali vnetje.
17 Pharmacotherapeutic group:
Farmakoterapevtska skupina:
End of observation Time (h) after s. c. injection period *determined as amount of glucose infused to maintain constant plasma glucose levels (hourly mean values)
* določena kot količina infundirane glukoze, potrebna za vzdrževanje stalne koncentracije glukoze v plazmi (povprečne urne vrednosti)
18 In a clinical study, symptoms of hypoglycaemia or counter-regulatory hormone responses were similar after intravenous insulin glargine and human insulin both in healthy volunteers and patients with type 1 diabetes.
18 V klinični študiji so bili simptomi hipoglikemije in protiregulacijski hormonski odzivi po intravenski uporabi insulina glargin in humanega insulina pri zdravih prostovoljcih in bolnikih z diabetesom tipa 1 podobni.
Zinc chloride, m-cresol, glycerol, hydrochloric acid, sodium hydroxide, water for injections.
Cinkov klorid, metakrezol, glicerol, klorovodikova kislina, natrijev hidroksid, voda za injekcije.
6.3 Shelf life
19 6. 3 Rok uporabnosti
19 6.4 Special precautions for storage
6. 4 Posebna navodila za shranjevanje
Unopened cartridges Store in a refrigerator (2°C-8°C).
Neodprti vložki Shranjujte v hladilniku (2 °C - 8 °C).
3 ml solution in a cartridge (type 1 colourless glass) with a black plunger (bromobutyl rubber) and a flanged cap (aluminium) with a stopper (bromobutyl or laminate of polyisoprene and bromobutyl rubber).
3 ml raztopine v vložku (iz brezbarvnega stekla tipa 1) s črnim batom (iz brombutilne gume) s prirobljeno zaporko (iz aluminija), z zamaškom (iz brombutilne gume ali laminata poliizoprena in brombutila).
Insulin pen The cartridges are to be used in conjunction with an insulin pen such as OptiPen and other pens suitable for Lantus cartridges, and as recommended in the information provided by the device manufacturer.
Vložki se uporabljajo skupaj z insulinskim injekcijskim peresnikom kot je OptiPen in drugimi primernimi injekcijskimi peresniki za vložke zdravila Lantus in po navodilih izdelovalca injekcijskega peresnika.
If the pen malfunctions (see instructions for using the pen), the solution may be drawn from the cartridge into a syringe (suitable for an insulin with 100 Units/ ml) and injected.
Če se injekcijski peresnik pokvari (glejte navodila za uporabo injekcijskega peresnika), je mogoče raztopino potegniti iz vložka z brizgo (primerno za insulin s 100 enotami/ ml) in injicirati.
Cartridge Before insertion into the pen, the cartridge must be stored at room temperature for 1 to 2 hours.
Preden vstavite vložek v injekcijski peresnik, ga morate pustiti na sobni temperaturi 1 do 2 uri.
Sanofi-Aventis Deutschland GmbH, D-65926 Frankfurt am Main, Germany
Sanofi- Aventis Deutschland GmbH, D- 65926 Frankfurt am Main, Nemčija.
22 To reduce the risk of nocturnal and early morning hypoglycaemia, patients who are changing their basal insulin regimen from a twice daily NPH insulin to a once daily regimen with Lantus should reduce their daily dose of basal insulin by 20-30% during the first weeks of treatment.
Bolniki, ki z insulina NPH dvakrat na dan preidejo na zdravilo Lantus enkrat na dan, morajo za zmanjšanje nevarnosti nočne in zgodnje jutranje hipoglikemije dnevni odmerek bazalnega insulina v
23 In case of insufficient glucose control or a tendency to hyper- or hypoglycaemic episodes, the patient's adherence to the prescribed treatment regimen, injection sites and proper injection technique and all other relevant factors must be reviewed before dose adjustment is considered.
23 V primeru nezadostne urejenosti glukoze ali nagnjenosti k hiper - ali hipoglikemijam je treba pred spreminjanjem odmerka preveriti, ali bolnik upošteva predpisano shemo zdravljenja, mesta injiciranja, ustrezno tehniko injiciranja in vse druge pomembne dejavnike.
adrenocortical insufficiency),
- sočasno zdravljenje z določenimi drugimi zdravili.
24
24 Sočasne bolezni
25 The patient's ability to concentrate and react may be impaired as a result of hypoglycaemia or hyperglycaemia or, for example, as a result of visual impairment.
Bolnikova zmožnost koncentracije in reagiranja se lahko poslabša zaradi hipoglikemije ali hiperglikemije, pa tudi npr. zaradi prizadetosti vida.
Patients should be advised to take precautions to avoid hypoglycaemia whilst driving.
25 Bolnikom je treba svetovati, naj upoštevajo ustrezne varnostne ukrepe, da bi se izognili hipoglikemiji med upravljanjem vozila.
26 Eyes disorders
Očesne bolezni
Skin and subcutaneous tissue disorders
26 Bolezni kože in podkožja
27 More severe episodes with coma, seizure, or neurologic impairment may be treated with intramuscular/ subcutaneous glucagon or concentrated intravenous glucose.
Hujše primere s komo, generaliziranimi krči ali nevrološko prizadetostjo je mogoče zdraviti z glukagonom intramuskularno ali subkutano oz. s koncentrirano glukozo intravensko.
28 The following graph shows the results from a study in patients:
Spodnji graf prikazuje rezultate študije pri bolnikih: